Clinical trials · Charlotte, NC
Cancer clinical trials in Charlotte
We’re tracking 190 recruiting cancer studies with a site in or near Charlotte — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Charlotte
- NCT05696782RecruitingPhase 2
Durvalumab after chemoradiation for stage III lung cancer
This trial tests giving durvalumab (an immune therapy) soon after standard chemotherapy and radiation for stage II–III non-small cell lung cancer that cannot be removed by surgery. The goal is to see if this “quick start” approach improves outcomes compared with waiting longer to begin durvalumab.
Charlotte, North CarolinaAges 18 years+ - NCT05413421RecruitingPhase 1
ORIC-944 for metastatic prostate cancer after hormone therapy
This early-phase trial tests ORIC-944 to see how well it works and what dose is safest for metastatic prostate cancer that has progressed after hormone-targeted pills. It may help people whose cancer has stopped responding to prior prostate cancer hormone treatments.
Charlotte, North CarolinaAges 18 years+ - NCT04546399RecruitingPhase 2
Blinatumomab with or without nivolumab for first relapse ALL
This study compares blinatumomab alone versus blinatumomab plus nivolumab in young people whose B-cell ALL has returned for the first time. It aims to see whether adding nivolumab improves control of the leukemia after relapse.
Charlotte, North CarolinaAges 1–30 - NCT05894239RecruitingPhase 3
Tested targeted drug for HER2-positive breast cancer with PIK3CA changes
This Phase 3 study tests inavolisib plus Phesgo versus placebo plus Phesgo in people whose breast cancer has both HER2-positive and PIK3CA-mutated tumor markers. The goal is to see if adding inavolisib improves how well the treatment controls the cancer and how safe it is.
Charlotte, North CarolinaAges 18 years+ - NCT07009093Recruiting
Mobile app for young women with breast cancer
This study tests a mobile app called Mighty Pro to help young women with breast cancer manage stress. It is for women ages 18–45 who are patients at a specific cancer center and feel some distress.
Charlotte, North CarolinaAges 18–45 - NCT07046936Recruiting
Mitochondria and resilience in gynecologic cancer
This study looks at how cell energy (mitochondria) relates to a person's ability to bounce back during treatment for advanced ovarian or endometrial cancer. If you qualify, you'll have tissue and blood samples analyzed alongside standard therapy to help find why some people handle treatment better than others.
Charlotte, North CarolinaAges 50 years+ - NCT05145400RecruitingPhase 2
Drug treatment for frail or older newly diagnosed multiple myeloma
This Phase 2 study tests whether “isa-Rd” can safely and effectively treat people who have newly diagnosed multiple myeloma and are frail or much older. It may help those who are at higher risk of side effects from stronger, full-intensity chemotherapy.
Charlotte, North CarolinaAges 18 years+ - NCT05675410RecruitingPhase 3
Testing two-drug treatment versus standard for Hodgkin lymphoma
This Phase 3 study compares today’s standard treatment for classic Hodgkin lymphoma with a new combination using brentuximab vedotin and nivolumab. The goal is to see which approach works better and is safe for newly diagnosed patients with early-stage disease.
Charlotte, North CarolinaAges 5–60 - NCT04948619RecruitingPhase 2
Vaccine response after cancer therapy in kids
This study is checking how well the immune system works and responds to vaccines in children and young adults who have recently finished cancer treatment. It may help doctors understand if vaccines are safe and effective after therapy.
Charlotte, North CarolinaAges 2–21 - NCT05554406RecruitingPhase 2
New drug therapy for high-risk AML
This trial is testing new drug combinations for people with newly diagnosed, high-risk AML who have not yet started treatment. It aims to find more effective therapies for this aggressive form of leukemia.
Charlotte, North CarolinaAges 18–59 - NCT07060807RecruitingPhase 3
Patritumab deruxtecan for advanced breast cancer
This study tests an investigational drug called patritumab deruxtecan for people with a certain type of advanced breast cancer that is hormone receptor-positive and HER2-negative. The drug targets a protein called HER3, which is common on these cancer cells, and may slow or shrink the cancer when previous treatments have stopped working.
Charlotte, North CarolinaAges 18 years+ - NCT05612347Recruiting
Compare stool test vs colonoscopy for older adults with polyps
This study compares two ways to check for colon polyps in older adults: using a stool test versus having a colonoscopy. It may help find a simpler option if you only had a small number of lower-risk polyps before.
Charlotte, North CarolinaAges 65–82 - NCT05624996RecruitingPhase 3
Targeted high-dose radiation added to standard lung cancer treatment
This trial tests whether adding high-dose, targeted radiation to the usual treatment helps people with locally advanced, non-operable lung cancer live longer or better control the cancer. It may help shrink tumors in the chest and improve outcomes when surgery can’t be done.
Charlotte, North CarolinaAges 18 years+ - NCT07061977RecruitingPhase 3
New cancer drug combo for advanced cervical cancer
This trial tests if giving the immunotherapy drug pembrolizumab before and after standard chemoradiation works better than the standard approach for people with high-risk cervical cancer that has spread locally.
Charlotte, North CarolinaAges 18 years+ - NCT05564390RecruitingPhase 2
MyeloMATCH screening to match you to AML or MDS treatment
This study screens people with newly suspected acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) to see which treatment approach fits best—either a specific study treatment or standard care. It may help by directing you to the right option and by sharing your blood/bone marrow samples for research.
Charlotte, North CarolinaAges 18 years+ - NCT05633615RecruitingPhase 2
Testing new drug options after CAR T for aggressive lymphoma
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
Charlotte, North CarolinaAges 18 years+ - NCT03851445RecruitingPhase 2/Phase 3
Lung cancer screening trial using tumor and blood test results
This trial helps sort people with previously treated lung cancer into the best next treatment options by using new tumor tissue (and sometimes blood) test results. It may help you get matched to therapies based on features like PD-L1 and other biomarkers.
Charlotte, North CarolinaAges 18 years+ - NCT06014658RecruitingPhase 1/Phase 2
Study of MBRC-101 for advanced solid tumors
This trial tests a new drug, MBRC-101, that targets a protein called EphA5 found on some cancer cells. It is for people with advanced solid tumors (like lung, breast, or pancreatic cancer) that have stopped responding to other treatments. The study aims to find a safe dose and see if the drug can shrink tumors.
Huntersville, North CarolinaAges 18 years+ - NCT05431270RecruitingPhase 1/Phase 2
Test drug that targets CD73, alone or with immunotherapy
This early-stage study tests mavrostobart (an anti-CD73 antibody) to see what dose is safe and whether it can help shrink tumors. It’s studied by itself and also with a PD-1 immune therapy or chemotherapy, depending on your cancer type and prior treatments.
Huntersville, North CarolinaAges 18 years+ - NCT06751329RecruitingPhase 1/Phase 2
Study of DM002 for advanced solid tumors
This trial tests a new drug called DM002 for people with advanced solid tumors that have not responded to standard treatments. The drug targets two proteins (MUC1 and HER3) found on some cancer cells, and may help shrink tumors or slow their growth.
Huntersville, North CarolinaAges 18 years+ - NCT07218003Enrolling by invitationPhase 1
Study of RNDO-564 alone or with pembrolizumab for bladder cancer
This trial tests an experimental drug, RNDO-564, either by itself or combined with another drug (pembrolizumab), for people with advanced bladder cancer or other solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow cancer growth.
Huntersville, North CarolinaAges 18 years+ - NCT06040541RecruitingPhase 1
Study of RMC-9805 for KRAS G12D solid tumors
This trial tests an experimental pill (RMC-9805) for people with solid tumors that have a specific KRAS G12D mutation. It's for those who have already tried other treatments and need new options.
Huntersville, North CarolinaAges 18 years+ - NCT07109726RecruitingPhase 1/Phase 2
Testing TER-2013 for advanced tumors with AKT/PI3K/PTEN changes
This trial tests a new drug called TER-2013, alone or combined with another drug (fulvestrant), for people with advanced solid tumors that have specific genetic changes in the AKT/PI3K/PTEN pathway. It aims to see if the drug is safe and effective.
Huntersville, North CarolinaAges 18 years+ - NCT06999187RecruitingPhase 1
Study of DR-0202 for advanced solid tumors after multiple treatments
This trial tests a new drug, DR-0202, for people with certain advanced cancers that have not responded to at least two prior treatments. It may be an option if standard treatments are no longer working.
Huntersville, North CarolinaAges 18 years+
Hear when a new Cancer trial opens near Charlotte, NC
We’ll email you when one opens near Charlotte, NC — at most once a week, no account needed, unsubscribe anytime.
Cancer trials in other cities
Where these studies are running near Charlotte
Institutions with a site for the recruiting cancer studies listed above.
- Carolinas Medical Center/Levine Cancer Institute · 7 studies
- Novant Health Presbyterian Medical Center · 5 studies
- Carolina BioOncology Institute · 4 studies
- Levine Cancer Institute · 4 studies
- Atrium Health Cabarrus · 3 studies
- Atrium Health Levine Cancer Institute · 3 studies
- Gibbs Cancer Center-Gaffney · 3 studies
- Matthews Radiation Oncology Center · 2 studies
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting cancer studies in North Carolina.
Common questions
- Are there cancer clinical trials near Charlotte?
- Yes. We're currently tracking 190 recruiting cancer studies with a site near Charlotte, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study near Charlotte?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Charlotte to take part?
- Not necessarily. These studies have a site near Charlotte, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open near Charlotte regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.